The Th1/Th2 cell ratio was elevated after the 12th conception, but the patient miscarried, with a normal karyotype of chorionic villi despite the immunosuppressive treatment. After the 13th conception, she began receiving treatment with 2 mg/d of tacrolimus at 4 weeks' gestation, which was continued until delivery.
Results:
The Th1/Th2 cell ratio was elevated after the 12th conception, but the patient miscarried, with a normal karyotype of chorionic villi despite the immunosuppressive treatment. After the 13th conception, she began receiving treatment with 2 mg/d of tacrolimus at 4 weeks' gestation, which was continued until delivery.
Conclusion:
For recurrent miscarriage cases that show an elevated Th1/Th2 cell ratio after achieving pregnancy, immunosuppressive treatment with tacrolimus could be effective.
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| INTRODUCTION
Type-1 T helper (Th1) and type-2 T helper (Th2) cells play important roles in immune responses, particularly in immune rejection and tolerance. 1, 2 Hence, a method to achieve Th1/Th2 balance has been proposed to offset materno-fetal immune reactions during pregnancy.
Pregnancy is generally associated with Th2 cell dominance except during instances of implantation and parturition. Over-reactive Th1 cell immune responses at the time of implantation have been associated with implantation failure, early pregnancy losses and repeated pregnancy losses [3] [4] [5] [6] and can be compared to an allograft rejection. 7 Immunological rejection might be one of the causes of miscarriage 8 and several immunomodulation therapies such as prednisolone, γ-globulin therapy, and allogenic leukocyte immunization have been used for these types of patients. These therapies have their own demerits, which are disadvantages for both the patient and the fetus.
The patient described here was found to have an impaired Th2 dominance after the establishment of pregnancy. The administration of an immunosuppressive agent allowed the patient to continue her pregnancy, and she had a successful delivery.
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| CASE REPORT
The histories of this patient's miscarriages are summarized in Table 1 .
She had received no treatment before her 1st and 2nd miscarriages. On her 13th conception, she received only immunosuppressive treatment (tacrolimus; 2 mg/d) that was started at 4 weeks' gestation after a home pregnancy test was positive, and she continued this dose until the day of delivery. A fetal heartbeat was confirmed at 6 weeks' gestation, but the fetal growth was small for gestational age. The pregnancy was monitored with serial ultrasonography and complicated by intrauterine growth restriction; therefore, the patient was moved from our clinic to the National Center for Child Health and Development. The patient's blood pressure was found to be elevated at around 24 weeks gestation, and she was treated with an antihypertensive drug. As a result of poor fetal growth velocity detected by serial ultrasonography and an inability to control her blood pressure, at 29 weeks a cesarean section was performed that resulted in the birth of a female infant weighting 748 g. Her physical condition improved rapidly after giving birth, and she was discharged 2 weeks after delivery. The baby girl was placed in the neonatal care unit (NICU), where
her weight increased at a good rate, and she was discharged 3 months after birth without complications.
| DISCUSSION
This case report is interesting because it is a case of immunosuppressive treatment using tacrolimus for a patient who showed an elevated Th1/Th2 cell ratio after conception in recurrent miscarriages. In this case, the patient miscarried at 8 weeks' gestation despite receiving intravenous massive immunoglobulin (IVIG) following the 11th conception, which marked her longest period without miscarriage.
Locally, we believed that IVIG could be effective for this case, and suspected that a cause of her miscarriages might be an immunological rejection. Therefore, we checked the levels of Th1 and Th2 cells in the non-pregnant period after the 11th miscarriage. However, she showed a normal Th1/th2 cell ratio, according to our criteria. 3 On the 12th pregnancy, the patient received immunosuppressive treatment (tacrolimus 1 mg/d) with empirical low-dose aspirin and There were no data concerning the Th1/Th2 ratio between the 12th and 13th pregnancies. However, the Th1/Th2 ratio was checked on October 1, 2012, on the day the patient was diagnosed with her 10th miscarriage (Table 3 ). Seven months after the 10th miscarriage, her Th1/Th2 was checked again, and it was confirmed that the Th1/ Th2 ratio was less than 10.3, and lower than that at the previous check.
When this patient was not pregnant, her Th1/Th2 ratio was less than 10.3. Therefore, the Th1/Th2 ratio was thought to have decreased to less than ten after her 12th miscarriage.
After the 13th conception, she began receiving treatment with tacrolimus of 2 mg/d at 4 weeks' gestation until delivery with no further anticoagulant therapy. During the patient's 13th pregnancy, the combination of tacrolimus and massive IVIG was an option for immunomodulation, but the patient did not agree to the use of IVIG due to its cost (1 million JPY/one treatment), therefore, we abandoned the combination of massive IVIG and tacrolimus, and decided to simply increase the dose of tacrolimus.
The embryo expresses paternal antigens that are foreign to the mother and therefore may be viewed as an allograft; in a normal pregnancy, the embryo is not rejected by the mother's immune system. This FKBP12-FK506 complex interacts and inhibits calcineurin, and further inhibits both T-lymphocyte signal transduction and IL-2 transcription. 11 The values for short-term immunosuppression and graft survival by patients are found to be similar between the two drugs.
However, tacrolimus results in a more favorable lipid profile which may have important long-term implications given the prognostic influence of rejection on graft survival. 12 In the present case, the cause of the patient's miscarriages was difficult to determine, because her elevated Th1/Th2 cell ratio was detectable only when she became pregnant. Tacrolimus is a major immune-suppressive agent for allogenic organ transplantation, but it has never been used for the treatment of recurrent miscarriages due to immunological rejection. This patient is an identical twin, and her sister had two children without a history of miscarriage. Based on the history of her sister, the cause of the patient's miscarriages was thought to be immunological rejection against the paternal antigen, which might have been acquired after birth.
